NYSE
146.18USD
-0.97 (-0.66%)
We have scored 106 news catalysts on Merck & Co., Inc. (MRK) over the past 12 months. The biggest single-day move next to one of them came Jun 23, 2026, when MRK closed +3.6%: “Bank of America Sees Interest Rates Exploding Higher Soon: Play It Safe With 4 Dividend Giants”. Coverage across the window leans positive (average ticker sentiment +0.35). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
361B
P/E
—
EPS
—
Beta
0.23
52W range
77.58-156.92
Day range
145.75–147.84
Open
147.08
Prev close
147.15
Volume
2.2M
Avg volume
10.2M
Dividend
3.40
IPO
1978-01-13
Analysts publish price targets on MRK, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
24 analyst price targets from $105 to $180
as of 2026-09-11
The market is within 4% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Merck & Co., Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Merck & Co., Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for MRK: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
The price sits at the 25th percentile of 24 published models, endorsing the near-consensus around $150 but explicitly declining to pay for the bull case of $170-$180 or accept the bear case of $105-$116.
What the disagreement turns on
Does the mRNA cancer vaccine expand Keytruda's effective patent life and total addressable market enough to justify the 12.2% revenue growth the price requires, and the available data cannot settle this because clinical trial outcomes are not a wired observable.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
